LS411NHomo sapiens (Human)Cancer cell line
Also known as: LS411, LS 411, LS-411, LS-411N
Quick Overview
Human colorectal cancer cell line with known genetic mutations and drug sensitivity profiles.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1385 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Cecum[UBERON:UBERON_0001153] |
Donor Information
| Age | 32 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
| Subtype Features | MSI |
Disease Information
| Disease | Cecum adenocarcinoma |
|---|---|
| Lineage | Bowel |
| Subtype | Colon Adenocarcinoma |
| OncoTree Code | COAD |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000985_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Tyr126Ter (c.378C>G) | Homozygous | - | from parent cell line T24 |
| MutationSimple | PTEN | p.Lys164Argfs*3 (c.491delA) | Unspecified | - | PubMed=32321971 |
| MutationSimple | PTEN | p.Cys105Valfs*8 (c.313delT) | Heterozygous | - | from parent cell line LS411N |
| MutationSimple | BRAF | p.Val600Glu (c.1799T>A) | Unspecified | - | PubMed=26214590 |
| MutationSimple | APC | p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA) | Heterozygous | - | from parent cell line WiDr |
| MutationSimple | APC | p.Gln789Ter (c.2365C>T) | Heterozygous | - | from parent cell line LS411N |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Nat. Commun. 10:3574.1-3574.11(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
Pharmacoproteomic characterisation of human colon and rectal cancer.
Weichert W., Knapp S., Feller S.M., Kuster B.
Mol. Syst. Biol. 13:951-951(2017).
Genomic determinants of protein abundance variation in colorectal cancer cells.
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.
Cell Rep. 20:2201-2214(2017).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)/villin mRNA expression.
Tollenaar R.A.E.M., Rombouts Y., Wuhrer M.
Mol. Cell. Proteomics 15:124-140(2016).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.
Nat. Commun. 6:7002.1-7002.10(2015).
Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.
Mariadason J.M., Sieber O.M.
Cancer Res. 74:3238-3247(2014).
Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.
Grade M., Gaedcke J.
Radiother. Oncol. 108:451-457(2013).
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.
Orphanides G., French T., Wessels L.F.A.
BMC Med. Genomics 5:66.1-66.15(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.
Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.
Br. J. Cancer 103:340-346(2010).
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.
Cancer Res. 70:5901-5911(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.
Camps J., McNeil N.E., Difilippantonio M.J., Ried T.
Genes Chromosomes Cancer 49:204-223(2010).
Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.
Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.
Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.
Garcia-Foncillas J.
Mol. Cancer 5:29.1-29.10(2006).
Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines.
Liu Y., Bodmer W.F.
Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
Mutations of the BRAF gene in human cancer.";
Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Nature 417:949-954(2002).
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
Wolf E., Gabius H.-J.
J. Cancer Res. Clin. Oncol. 127:375-386(2001).
Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement.
Bicknell D.C., Bodmer W.F., Arends M.J., Wyllie A.H., Edwards P.A.W.
Proc. Natl. Acad. Sci. U.S.A. 98:2538-2543(2001).
APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.
Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.
Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line.
Suardet L., Li C., Little J.B.
Int. J. Cancer 68:126-131(1996).
Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines.
Bodmer W.F.
Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993).
Responsiveness of three newly established human colorectal cancer cell lines to transforming growth factors beta 1 and beta 2.
Eliason J.F., Odartchenko N.
Cancer Res. 52:3705-3712(1992).